R U READY ??
$ATTBF - 10K is out!
Overall strategy:
Medical marijuana laws have changed in the US and laws are being confirmed in Canada. New markets are continually opening up, and there is a massive need to develop, as plant-based phyto compounds appear to be in huge demand globally. Pharma companies have patents expiring and the Abattis/Vertical capabilities create solutions to these market needs. 2013 was another milestone year for Abattis in its pursuit of becoming the world's first fully integrated bioceutical company and it brings the Company another step closer to implementing the Company’s Grow, Dry, Extract, Refine and Sell (GDERS) model.
Moreover, continuing research and development is being conducted by the Company while it is preparing and filing MMPR license applications. The Company recognizes the newly emerging opportunity in connection with medical marijuana and further integrates it into the Company’s overall botanical strategy. As the regulatory environment in Canada and in the US on Cannabis changed during this reporting period, the Company, with its research team and growing equipment, and proprietary extraction equipment, the Company has the ability to be a leader in the medical marijuana industry worldwide. The recent acquisition of exclusive worldwide rights to patent pending proprietary technologies to produce and deliver highly effective phyto-compounds for use in nutraceuticals, topical crèmes, medical foods, botanical drugs and pharmaceuticals. The management's expertise enables the Company to produce bio-pharma proteins and compounds to meet all federal regulations and laws.
Abattis will now control its own proprietary and pending patented products from seed to producing finished product at facilities owned by its wholly-owned subsidiary, Northern Vine Canada Inc. The Company believes this gives the Company a competitive edge in the markets that the Company has identified. The Company can ensure control in the supply chain and traceability at a Drug and Pharma level for its ingredients and finished products. The Company plans to target expansion of turn-key operations throughout Canada and the USA.
The Company has identified several other botanicals as candidates to produce. These include rose periwinkle for leukemia, anemia malaria, and for serotonin and melatonin.
